Population Pharmacokinetics and Exposure–Response Relationships of Etrolizumab in Patients with Moderately-to-Severely Active Crohn's Disease

MIDD

Regulatory interactions

Pharmacometrics

Gastroenterology

J Clin Pharmacol. 2025 May 22. Online ahead of print.

Moein A, Ribbing J, Ibrahim MMA, Zhang W, Kassir N

New publication, in collaboration with Genentech, on etrolizumab for treatment of Crohn’s disease (CD), a chronic inflammatory bowel disease (IBD) that can cause severe complications, significantly impacting patient quality of life. To develop effective biologic treatments such as etrolizumab, it’s crucial to gain a clear understanding of its pharmacokinetics (PK) and its relationship to patient response. This work provides a strong showcase for how strategic submission analyses and efficient pharmacometrics can significantly cut reporting timelines.

This analysis provides key insights into the drug's behavior using an efficient modeling strategy:

Time-varying clearance - the analysis confirmed that, as with other monoclonal antibody therapies (mAbs) in IBD, etrolizumab clearance decreases over the course of treatment, likely due to a reduction in disease activity.
The population PK analysis (based on 2312 patients with CD or ulcerative colitis, assigned to active Etrolizumab) estimated an eventual 22% reduction in CL (albeit with high between-subject variability).
Addressing confounding: to avoid confounding between disease improvement and drug exposure in the Exposure-Response (ER) analysis, the initial Week 4 "trough" concentration was used as the key independent exposure metric.
The subsequent decrease in clearance did not affect exposure during the first dosing interval.
Other confounding covariates were also accounted for in the ER analyses.
Modeling efficiency - by using logistic regression information in landmark analyses of various outcomes, the team was able to shorten the analysis and reporting phase significantly.